Skip to main content

Sutro Biopharma, Inc.

corporate_fare Company Profile

Sutro Biopharma, Inc.

STRO·NASDAQ·Life Sciences·CIK 0001382101

The company is a clinical stage oncology company that develops site-specific and novel-format antibody drug conjugates (ADCs). It uses its proprietary integrated cell-free protein synthesis platform, XpressCF®, and its site-specific conjugation platform, XpressCF+®, to design and develop therapeutics. These therapeutics include ADCs, bispecific ADCs, immunostimulatory ADCs (iADCs), and dual-payload ADCs (dpADCs), primarily targeting clinically validated targets where current treatments are suboptimal. The company's highest priority wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor (TF), which is being developed for the treatment of solid tumors. An Investigational New Drug (IND) application for STRO-004 was filed and cleared in October 2025, and a Phase 1 trial began in November 2025. This open-label, multicenter trial evaluates the safety, pharmacokinetics, and preliminary anti-tumor activity of STRO-004 in patients with advanced TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The dose-escalation phase includes multiple cohorts with ascending dose levels. Dosing of patients in dose level 2 was completed in February 2026, and dosing in the dose level 3 cohort began in February 2026. The company's preclinical assets include STRO-227 and STRO-006.

Sutro Biopharma, Inc. (NASDAQ:STRO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for STRO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for STRO spans 10-Q, 8-K, 424B3, S-3.

Recent high-impact activity:

  • Sutro 10-Q: Q3 Revenue $9.1M Misses, Cash $142.2M Funds Runway Into 1H 2028
  • Sutro Q3 Revenue Misses Estimates at $9.1M, Net Loss Widens to $31.5M
  • Sutro Biopharma Plunges 24% as STRO-004 Update Disappoints
  • Sutro's STRO-004 Shows Early Responses in Phase 1, Cash Runway Extended to Q2 2028
  • Q1 Net Loss Halved, Cash Position Boosted by $110M Offering, Extending Runway

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$102.48M
Net Income
-$191.09M
Diluted EPS
-$22.49
Op. Cash Flow
-$177.23M
Operating Income
-$158.37M
Cash & Equivalents
$58.13M
Debt / Equity
0.00×
Net Margin
-186.5%
Shares Outstanding
8.58M sh
Source: 10-K · filed 2026-03-23 · accession 0001193125-26-119873

Short Interest & Short Volume

6.26 days to cover

FINRA reported short interest of 2,257,487 shares in STRO as of the October 30, 2026 settlement, a 15.1% increase from the prior period — about 6.3 days to cover at its recent average daily volume. On November 20, 2026, 74.0% of STRO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,257,487 shares as of October 30, 2026
Change vs prior period▲ 15.1%
Days to cover6.26 at avg daily volume of 360,485
Daily short volume (FINRA facilities)74.0% of 93,613 shares on November 20, 2026
5-day average short volume57.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with S →
$8.6
52-week range · as of 2026-11-12 $7.15 – $43.85
Market cap
$142.77M
Volume
275.9K (0.8× avg)
3-mo avg 331.5K
Live data · 2026-11-21 05:20 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed STRO - Latest Insights

STRO
Nov 12, 2026, 5:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.59
Real-time Price: $8.60 info
Change: -$0.990 (-10%) info
Market Cap: $142.772M info
STRO
Nov 12, 2026, 4:31 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.59
Real-time Price: $8.60 info
Change: -$0.990 (-10%) info
Market Cap: $142.772M info
STRO
Aug 12, 2026, 2:04 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $21.83
Real-time Price: $8.60 info
Change: -$13.23 (-61%) info
Market Cap: $142.772M info
STRO
Aug 12, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $24.67
Real-time Price: $8.60 info
Change: -$16.07 (-65%) info
Market Cap: $142.772M info
STRO
May 14, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $38.42
Real-time Price: $8.60 info
Change: -$29.82 (-78%) info
Market Cap: $142.772M info
STRO
May 14, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $38.42
Real-time Price: $8.60 info
Change: -$29.82 (-78%) info
Market Cap: $142.772M info
STRO
May 14, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $38.42
Real-time Price: $8.60 info
Change: -$29.82 (-78%) info
Market Cap: $142.772M info
STRO
May 04, 2026, 7:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $38.00
Real-time Price: $8.60 info
Change: -$29.40 (-77%) info
Market Cap: $142.772M info
STRO
Apr 19, 2026, 7:45 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $31.55
Real-time Price: $8.60 info
Change: -$22.95 (-73%) info
Market Cap: $142.772M info
STRO
Apr 01, 2026, 5:18 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $24.87
Real-time Price: $8.60 info
Change: -$16.27 (-65%) info
Market Cap: $142.772M info
STRO
Mar 23, 2026, 5:23 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $21.33
Real-time Price: $8.60 info
Change: -$12.73 (-60%) info
Market Cap: $142.772M info
STRO
Mar 23, 2026, 4:44 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $21.33
Real-time Price: $8.60 info
Change: -$12.73 (-60%) info
Market Cap: $142.772M info
STRO
Mar 23, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $21.33
Real-time Price: $8.60 info
Change: -$12.73 (-60%) info
Market Cap: $142.772M info
STRO
Mar 23, 2026, 4:05 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $21.33
Real-time Price: $8.60 info
Change: -$12.73 (-60%) info
Market Cap: $142.772M info
STRO
Feb 10, 2026, 5:16 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $15.03
Real-time Price: $8.60 info
Change: -$6.43 (-43%) info
Market Cap: $142.772M info
STRO
Feb 10, 2026, 5:11 PM EST
Filing Type: 424B5
Importance Score:
9
Price at Filing: $15.64
Real-time Price: $8.60 info
Change: -$7.04 (-45%) info
Market Cap: $142.772M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets